NEWS
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
Verrica Pharmaceuticals announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, an investigational oncolytic peptide-based immunotherapy for basal cell carcinoma(BCC). Key findings include:
- No treatment-related serious adverse events reported
- Overall 86% reduction in tumor size for all treated lesions
- 51% of lesions achieved complete histological clearance
- Patients with residual tumor achieved an average 71% reduction in tumor size
The company views VP-315 as a potential first-line therapy for BCC, with possible use in primary and neoadjuvant settings. Verrica plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine next steps for VP-315's development.
- No treatment-related serious adverse events reported
- Overall 86% reduction in tumor size for all treated lesions
- 51% of lesions achieved complete histological clearance
- Patients with residual tumor achieved an average 71% reduction in tumor size
The company views VP-315 as a potential first-line therapy for BCC, with possible use in primary and neoadjuvant settings. Verrica plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine next steps for VP-315's development.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1259Followers
76Following
8844Visitors
Follow
104420042 : doesn't matter. drop like crazy